Qi deng

Qideng Pharmaceutical is an innovative biotechnology company headquartered in Suzhou, China, focusing on the field of targeted protein degradation. The company utilizes its proprietary PROTAC (Proteolysis-Targeting Chimera) technology platform to develop small molecule drugs for "undruggable" targets in oncology. Its lead programs, such as QD-001 and QD-002, are designed to treat hormone-sensitive cancers like prostate and breast cancer by degrading the androgen and estrogen receptors, respectively. Qideng is committed to advancing precision medicine through its robust R&D capabilities and strategic location in the Suzhou Biobay. The company has successfully raised capital from leading venture investors to accelerate its pipeline toward clinical trials. By targeting proteins that are resistant to traditional inhibitors, Qideng aims to provide new therapeutic options for patients with advanced malignancies.